What is the recommended management, including complement‑C5 inhibition, for a non‑diabetic patient in his early 30s with BMI 20, severe hypertension, atypical arteriosclerosis, recurrent stage 1 acute kidney injury associated with chronic hemoglobinuria and an abnormal complement panel?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 8, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Complement-Mediated Thrombotic Microangiopathy (Atypical HUS) with C5 Inhibition

This patient requires immediate initiation of complement C5 inhibition (eculizumab or ravulizumab) given the constellation of chronic hemoglobinuria, recurrent AKI episodes coinciding with hemoglobinuria escalations, abnormal complement panel, severe hypertension, and early arteriosclerosis in a young non-diabetic patient—all hallmarks of complement-mediated thrombotic microangiopathy (atypical hemolytic uremic syndrome). 1, 2

Immediate Management Algorithm

Step 1: Initiate C5 Inhibition Urgently

  • Start eculizumab (900 mg IV weekly × 4 weeks, then 1200 mg at week 5, then 1200 mg every 2 weeks) or ravulizumab (weight-based single loading dose, then maintenance every 8 weeks) 1, 3, 4
  • Do not delay treatment for genetic testing results—the median time to treatment initiation in real-world cohorts is 8-10 days, but earlier is better to prevent irreversible kidney damage 3, 4
  • Meningococcal vaccination is mandatory before or concurrent with first dose (give prophylactic antibiotics if vaccination cannot precede treatment) 1

Step 2: Blood Pressure Control

  • Target BP <130/80 mmHg given the proteinuric kidney disease (evidenced by recurrent AKI and complement-mediated injury) 5, 6
  • First-line: ACE inhibitor or ARB titrated to maximum tolerated dose 5, 6, 7
  • Add thiazide or thiazide-like diuretic as second agent 5, 7
  • Add long-acting calcium channel blocker if needed for third agent 5
  • Avoid combining ACE inhibitor with ARB—this combination increases risk without benefit in non-proteinuric CKD and is not recommended 5, 8

Step 3: Confirm Diagnosis While Treating

  • Genetic testing for complement regulatory proteins: CFH, CFI, CFB, C3, MCP, CFHR1/3 deletions 3, 4
    • CFH/CFHR variants found in 39% and CFI variants in 22% of aHUS patients 3
    • Presence or absence of mutations does not change acute management—treat regardless 4, 2
  • Baseline biomarkers: C5a, sC5b-9 (terminal complement), Ba (alternative pathway), thrombomodulin, d-dimer, prothrombin fragment F1+2 2
  • Renal biopsy if safe: Will likely show acute-on-chronic TMA with glomerulosclerosis and interstitial fibrosis (seen in 80-90% of cases) 3

Expected Response and Monitoring

Short-term (First 6 Months)

  • Hematologic normalization: Expect resolution of anemia and thrombocytopenia in ~90% of patients within weeks 3, 4
  • C3 normalization: Occurs in ~90% of patients 3
  • Renal recovery: 74% achieve dialysis independence; complete TMA response (≥25% improvement in creatinine) occurs in 32-50% by 6 months 4
  • Hemoglobinuria resolution: Terminal complement blockade (C5a, sC5b-9) normalizes within weeks 2

Long-term Monitoring

  • Continue C5 inhibition indefinitely in most cases—this is a genetic disease with ongoing complement dysregulation 4, 9
  • Alternative pathway markers (Ba) remain elevated despite complete C5 blockade, reflecting ongoing upstream complement activation and continued risk 2
  • Monitor for breakthrough hemolysis: Check LDH, haptoglobin, hemoglobin monthly initially, then quarterly 4

Critical Pitfalls to Avoid

  1. Delaying treatment for genetic confirmation: Genetic results take weeks; irreversible kidney damage occurs in days. Treat first, test concurrently 3, 4

  2. Stopping C5 inhibition prematurely: Even with clinical remission, complement dysregulation persists. In one cohort, 70% remained on therapy long-term due to relapse risk 4

  3. Misattributing to hypertensive emergency alone: The combination of hemoglobinuria, complement abnormalities, and recurrent AKI triggered by hemoglobinuria escalations cannot be explained by hypertension alone—this is complement-mediated TMA 10

  4. Inadequate BP control: Severe hypertension is both a trigger and consequence of complement-mediated endothelial injury. Aggressive BP management to <130/80 mmHg is essential 5, 6

  5. Expecting complete renal recovery: Only 32-50% achieve complete TMA response; 26% remain dialysis-dependent despite treatment, reflecting the severity of baseline kidney injury 4

Additional Supportive Care

  • Statin therapy: Initiate moderate-to-high intensity statin for cardiovascular risk reduction given early arteriosclerosis 6
  • Antiplatelet therapy: Consider low-dose aspirin given thrombotic microangiopathy and vascular disease 6
  • Infection prophylaxis: Trimethoprim-sulfamethoxazole while on C5 inhibition due to meningococcal risk 1, 11
  • Avoid nephrotoxins: NSAIDs, contrast agents, and other nephrotoxic exposures can trigger acute deterioration 12

Nuances in This Case

The absence of glucose in urine despite severe hypertension and kidney injury, combined with illness-triggered hemoglobinuria episodes and abnormal complement panel, strongly points to complement-mediated TMA rather than diabetic nephropathy, hypertensive nephrosclerosis, or other common causes of CKD in young adults. The recurrent stage 1 AKI exclusively during hemoglobinuria escalations represents acute-on-chronic complement-mediated injury 2, 10.

The severe hypertension and arteriosclerosis at age 30 reflect chronic endothelial damage from uncontrolled complement activation—eculizumab reduces endothelial damage markers (thrombomodulin) to near-normal levels and prevents progression 2.

Real-world data shows 90% survival with C5 inhibition versus historical mortality rates of 25% without treatment, making this a life-saving intervention 4.

References

Research

New Anticomplement Drugs in Nephrology: Mechanism and Indication.

Kidney & blood pressure research, 2026

Related Questions

In an asymptomatic non‑diabetic adult with acute kidney injury and suspected complement‑mediated thrombotic microangiopathy who reports large carbohydrate‑rich meals, what is the significance of ketonuria and does it require specific treatment?
Can a positive direct Coombs (direct antiglobulin) test be associated with thrombotic microangiopathy?
How is thrombotic microangiopathy diagnosed in a pregnant patient?
What is the recommended management for a patient with a pathogenic complement factor H (CFH) mutation in short consensus repeat (SCR) 20, persistently low C3, normal C4, mildly elevated soluble C5b‑9, low‑grade hemoglobinuria, and a kidney biopsy showing only arteriosclerosis without overt thrombotic microangiopathy?
How should I evaluate and manage a patient with suspected complement‑mediated thrombotic microangiopathy presenting with recurrent hemoglobinuria, stage III hypertension, proteinuria, oliguria, Raynaud phenomenon, pressure petechiae, intermittent platelet count drops of approximately 30 % with concurrent red‑cell mass loss, transient neurologic (TIA‑like) events, paroxysmal atrial fibrillation, gastrointestinal ischemia‑like symptoms, and a modestly low Factor D level?
In a patient with normal HbA1c, tightly regulated glucose (80‑95 mg/dL) even during stress and pregnancy, isolated glucosuria after a high‑carbohydrate meal, normal thyroid function, negative tests for paroxysmal nocturnal hemoglobinuria, Coombs, myoglobinuria, hematuria, pheochromocytoma, primary and secondary aldosteronism, and renal artery stenosis, and who meets criteria for stage 1 chronic kidney disease due to arteriosclerosis with an estimated glomerular filtration rate >100 mL/min/1.73 m², should complement‑C5 inhibition (eculizumab or ravulizumab) be initiated?
How should steroids be tapered in a patient with Cushing's disease who underwent pituitary surgery, with a day‑1 cortisol of 20 nmol/L, now on day 3 receiving hydrocortisone 50 mg three times daily?
What antibiotics are appropriate for a multi‑resistant Enterobacter cloacae infection?
How should the dosing of ceftazidime‑avibactam be adjusted for renal impairment?
Is it appropriate to taper hydrocortisone to 20 mg three times daily today and then 20 mg, 10 mg, and 10 mg tomorrow in a patient three days after pituitary surgery with a day‑1 cortisol of 20 nmol/L who is currently receiving hydrocortisone 50 mg three times daily?
Should azithromycin (Azee) be given together with the rest of the antitubercular therapy (ATT) for non‑tuberculous mycobacterial (NTM) management?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.